Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study

• Published in: Drug design, development and therapy development and therapy, 2019-11, Vol.13, p.3913-3918
• Main Authors: Zhang, Jindi, Li, Anyang, Jiang, Qi, Zheng, Feiyun, Zhu, Haiyan
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; apatinib; Bevacizumab; Cancer; Cancer patients; Cancer research; Cancer therapies; Cancer treatment; Carcinoma, Ovarian Epithelial - drug therapy; Chemotherapy; Disease control; Drug dosages; Drug Resistance, Neoplasm - drug effects; Drug therapy; epidermal growth factor receptor; Epidermal growth factors; Female; Gynecology; Health aspects; Hospitals; Humans; Hypertension; Maintenance; maintenance therapy; Medical research; Middle Aged; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - pharmacology; Original Research; Ovarian cancer; Ovarian Neoplasms - drug therapy; Patients; Platinum; platinum-resistant; Pyridines - administration & dosage; Pyridines - pharmacology; Recurrence (Disease); Side effects; Sorafenib; Survival; Tablets - administration & dosage; Tablets - pharmacology; Toxic diseases; Toxicity; Vascular endothelial growth factor
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S220847

To evaluate real-world use and outcomes of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer. This is an observational study. Patients with platinum-resistant recurrent epithelial ovarian cancer initiating apatinib treatment from January 2016 to December 2018 were included. The primary end point was progression-free survival. Other end points included overall survival, objective response rate, disease control rate, and toxicity. A total of 28 platinum-resistant epithelial ovarian cancer patients were enrolled in this study. Thirteen cases received apatinib as maintenance therapy following chemotherapy with a median progression-free survival of 6.0 months and a medium overall survival of 11.0 months. Four patients received apatinib as palliative following chemotherapy with 2 cases in progressive disease and 2 cases in stable disease. Eleven cases received apatinib alone as salvage therapy with a disease control rate of 81.8% and a median progression-free survival of 3.0 months. The most common adverse effects were hand-foot syndrome (53.57%), secondary hypertension (46.43%) and fatigue (14.29%). Five patients discontinued treatment due to grade 3 toxicities and 4 patients required dose reduction because of adverse effects. Apatinib produced moderate improvements in progression-free survival in patients with platinum-resistant epithelial ovarian cancer both as maintenance therapy following chemotherapy and as single-agent salvage therapy. Our study suggests that apatinib may be effective for women with platinum-resistant recurrent epithelial ovarian cancer.